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ARTAG in the basal forebrain: widening the
constellation of astrocytic tau pathology
Alan King Lun Liu, Marc H. Goldfinger, Hayleigh E. Questari, Ronald K. B. Pearce and Steve M. Gentleman*
Tauopathies are disorders characterised by the abnor-
mal accumulation of hyperphosphorylated tau protein
within neurons and glial cells. Alzheimer’s disease
(AD), the most common form of tauopathy, features
a stereotypical, staged progression of neurofibrillary
tangle (NFT) and neuritic tau pathology through the
brain [1]. However, age-related NFT and neuritic tau
pathologies have also commonly been identified in
cognitively normal and ‘tangle-only dementia’ cases in
the absence of amyloid-β peptide (Aβ) pathology. This
has now been given the term ‘primary age-related
tauopathy’ (PART) to distinguish it from AD [3]. Fur-
thermore, astroglial tau aggregations have been in-
creasingly recognised to be present within the aging
brain independently of any co-existing neuropatho-
logical disorders or cognitive impairment. This unique
astroglial tau pathology has been termed aging-related
tau astrogliopathy (ARTAG) [6]. ARTAG exists in two
distinct morphological forms as thorn-shaped astro-
cytes (TSA) and granular/fuzzy astrocytes (GFA). In
addition, these tau immunoreactive astrocytes show a
unique distribution within the brain, with TSA and/or
GFA commonly found in subpial, subependymal and
perivascular locations, as well as in clusters within
the white and grey matter.
In a large population-based cohort study, Wharton
and colleagues attempted to elucidate the relationship
between astroglial tau pathology and neuronal tau and
to correlate it with dementia status in aged brains [12].
Although no significant correlation was identified, astro-
glial tau pathology was found to be prevalent, with TSA
present in 40 % of the cases. In particular, the authors
mentioned that TSA are commonly found in a subpial
location inferior to the substantia innominata but no de-
tailed quantitative or morphological assessment was
described.
As part of our ongoing research related to basal fore-
brain pathology in Lewy body disorders (LBD), we noted
incidental ARTAG pathology in a significant number of
cases. We surveyed 702 consecutive cases from the Par-
kinson’s UK Tissue bank at Imperial College London
and 83 cases from Brains for Dementia Research (BDR)
tissue bank from Newcastle University, excluding those
with incomplete clinical histories, vascular pathology
and significant co-existing neuropathological comorbidi-
ties. We selected 199 cases with a neuropathological
diagnosis of pure LBD (BrainNet Europe Braak tau stage
<4) or AD together with 26 age-matched controls. Basal
forebrain sections containing the nucleus basalis of Mey-
nert were immunostained for tau (AT8) and 76 cases
(33.8 % of total) were found to display ARTAG. Our co-
hort is different from that in the Wharton et al study in
that the mean age of our cohort is younger (78.8 vs 85.9)
and we have a greater number of LBD cases compared
with their study. Out of 155 cases with a diagnosis of
Parkinson’s disease (PD), 48 (31.0 %) displayed ARTAG
pathology in the basal forebrain, compared with 25.0 %
in dementia with Lewy bodies (DLB) cases, 41.7 % in
AD cases and 50.0 % in controls (Table 1). However,
ARTAG within the basal forebrain does not seem to
correlate with cognitive decline as 29 out of 78 cases
(37.2 %) without cognitive impairment showed ARTAG
compared with only 47 out of 147 (32.0 %) in those with
cognitive impairment (Chi-square test p = 0.432), and
the two groups are age-matched (mean age 78.69 vs
78.90, t-test p = 0.854). ARTAG pathology appeared to
be more common in males (65.8 % of ARTAG-positive
cases) although this did not reach statistical significance
(Chi-square test p = 0.082). Consistent with the existing
literature, the presence of ARTAG pathology increases
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with age, from the age of 60 (Table 2). As a result,
the seemingly higher prevalence of ARTAG pathology
in control and AD cases may be due to the higher
age at death (mean = 87.75) compared with PD (mean
age at death = 77.25) and DLB cases (mean age at
death = 79.55). The perivascular distribution of ARTAG
pathology is of particular interest because a weakening of
the blood-brain barrier has also been associated with
increasing age [11].
Morphologically, astrocytic tau pathology seen in our
cohort was distinct from the tufted astrocytes seen in
progressive supranuclear palsy [13] and LBD [4], and the
astrocytic tau-positive inclusions in corticobasal degen-
eration and Pick’s disease [5]. 67 cases (88.16 %) had
only TSA, 3 (3.95 %) had GFA and 6 had both (7.89 %)
TSA and GFA. In terms of distribution of pathology,
ARTAG in the basal forebrain is most commonly found
perivascularly (42.53 %), and subpially (34.48 %) (Fig. 1,
Additional file 1: Table S1). However, within the anterior
basal forebrain (at the anterior commissure decussation
level, as previously delineated [8]), ARTAG is most
prevalent in the subpial location (39.13 %) followed by a
perivascular distribution (30.43 %). Using the severity of
deposition parameters suggested by Kovacs et al [6],
ARTAG was most commonly identified focally at the
intermediate (54.05 %) and posterior (51.61 %) levels of
the basal forebrain, but only occasionally at the anterior
level (41.38 %) of the basal forebrain.
ARTAG pathology in the aging brain shares a simi-
lar distribution and morphology to that seen in
chronic traumatic encephalopathy (CTE), a neurode-
generative sequala of repeated traumatic brain injury
[9]. Co-morbid neurodegenerative disorders have also
been identified within CTE cases [10]. Within a large
cohort of neurodegenerative diseases and controls,
Ling et al reported evidence of CTE pathology in 32
out of 268 (11.9 %) screened cases and in 12.8 % of
age-matched controls, and 30 (93.8 %) of CTE-
positive cases had history of traumatic brain injury
[7]. However, in another study where CTE pathology
was screened in cortical brain sections of 198 controls
and 66 individuals with a history of involvement in
contact sports [2], CTE pathology was only identified
in 21 of the 66 individuals at risk but not in the con-
trol group. This conflicting finding could be due to
the different age ranges of the cases screened in these
two studies. The 32 CTE-positive cases identified in
the Ling et al study were all over the age of 60 (mean
age = 80.97), and the 6 CTE-positive control subjects
had a mean age of 92.17 which is considerably higher
than the all cases screened in the Bieniek et al study
(mean age ~75). This suggests that CTE and ARTAG
possibly share a common aetiological pathway. The
predominance of ARTAG pathology in males in our
cohort is similar to that seen in CTE. Detailed retro-
spective clinical note analysis was not performed but
a number of cases had a recorded history of head in-
jury, participation in contact sport or military service.
Furthermore, CTE pathology may reflect advanced
aging or injury induced ARTAG or both. Wharton
and colleagues noted the presence of corpora amyla-
cea in close proximity to astroglial tau accumulations
[12], and we report a similar observation in the basal
forebrain (Fig. 1d). The accumulation of corpora amylacea
is hypothesised to be involved in a disposal pathway of tau
aggregates, which might further explain the close proxim-
ity of these bodies to tau pathology. Further work in a
large cohort is needed to examine the relationship be-
tween CTE and ARTAG pathology throughout the brain
and further clinicopathological research will add to our
understanding of the pathogenesis of CTE and ARTAG in
relation to the process of normal aging and neurodegener-
ative disorders.
Ethical considerations
The work conducted on human tissue was under ethical
approval held by the Parkinson’s UK Brain Bank at
Imperial College London (Registered charity in England
and Wales (258197) and in Scotland (SC037554);
Table 1 Demographics and presence of ARTAG pathology of screened cases
Primary neuropathological diagnosis Control Parkinson’s disease Dementia with Lewy bodies Alzheimer’s disease
n 26 155 20 24
M:F (% male) 8:18 (30.8 %) 98:57 (63.2 %) 13:7 (65.0 %) 11:13 (45.8 %)
Mean age at death (SD) 81.35 (10.159) 77.25 (7.685) 79.55 (6.160) 85.75 (5.848)
Cases with presence of ARTAG in basal forebrain (%) 13 (50.0 %) 48 (31.0 %) 5 (25.0 %) 10 (41.7 %)
Table 2 Presence of ARTAG pathology among different age
groups




50–59 0 (0.0 %) 4 (100.0 %)
60–69 7 (25.9 %) 20 (74.1 %)
70–79 21 (28.0 %) 54 (72.0 %)
80–89 40 (38.5 %) 64 (61.5 %)
90–99 8 (53.3 %) 7 (46.7 %)
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Multicentre Research Ethics Committee approval refer-
ence number: 07/MRE09/72). Parkinson’s UK Brain
Bank is an approved Research Tissue Bank by the Wales
Research Ethics Committee (Ref. No. 08/MRE09/31 + 5).
Further tissues were provided by the Newcastle Brain
Tissue Resource, which is funded in part by a grant from
the UK Medical Research Council (G0400074) and by
Brains for Dementia research, a joint venture between
Alzheimer’s Society and Alzheimer’s Research UK.
Additional file
Additional file 1: Additional information on case demographics and
qualitative/semi-quantitative assessment of ARTAG pathology with
summary of data. ARTAG pathology was semi-quantitatively rated 1-4
(low to high burden) under columns K-U. (XLSX 30 kb)
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AD: Alzheimer’s disease; ARTAG: Aging-related tau astrogliopathy; BDR: Brains
for Dementia Research; CTE: Chronic traumatic encephalopathy;
Fig. 1 Characteristic ARTAG astrocytic tau pathology seen in the basal forebrain around large vessels (a,b), in the subpial area at the ventral
surface of the brain (b) and periventricularly (c). Corpora amylacea around large vessels in close proximity to astrocytic tau pathology. Arrows
pointing to corpora amylacea (d). Scale bars = 50 μm for (a-d). H&E image of the human basal forebrain (adapted from [8]) with common areas
for ARTAG tau pathology outlined in dashed circles (e). Abbreviations: AC, anterior commissure; Cd, caudate; GP, globus pallidus; IC, internal
capsule; Ins Ctx, insula cortex; Pt, putamen
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DLB: Dementia with Lewy bodies; GFA: Granular/fuzzy astrocytes; LBD: Lewy
body disorders; NFT: Neurofibrillary tangle; PART: Primary age-related tauopa-
thy; PD: Parkinson’s disease; TSA: Thorn-shaped astrocytes.
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